Bianca A Lang

List of Publications by Year
in descending order

66 papers	4,210 citations	136885 32 h-index	118793 62 g-index
66 all docs	66 docs citations	66 times ranked	3720 citing authors

#	Article	IF	Citations
1	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.5	754
2	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	2.9	391
3	Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis and Rheumatism, 2000, 43, 541.	6.7	234
4	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.5	192
5	Treatment of dermatomyositis with intravenous gammaglobulin. American Journal of Medicine, 1991, 91, 169-172.	0.6	169
6	Primary juvenile fibromyalgia. Psychological adjustment, family functioning, coping, and functional disability. Arthritis and Rheumatism, 1997, 40, 752-760.	6.7	151
7	Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort study. Arthritis and Rheumatism, 2000, 43, 2402-2409.	6.7	124
8	Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: A national observational study. Arthritis Care and Research, 2012, 64, 122-131.	1.5	121
9	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	1.8	115
10	Pediatric onset of behcet's syndrome with myositis: case report and literature review illustrating unusual features. Arthritis and Rheumatism, 1990, 33, 418-425.	6.7	103
11	Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2012, 64, 546-553.	1.5	101
12	Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders. Journal of Bone and Mineral Research, 2015, 30, 1667-1675.	3.1	94
13	Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3408-3417.	1.8	93
14	Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. Journal of Rheumatology, 2010, 37, 1953-1961.	1.0	90
15	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care and Research, 2010, 62, 527-536.	1.5	86
16	Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study. Journal of Bone and Mineral Research, 2018, 33, 1435-1443.	3.1	79
17	Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2010, 62, 219-225.	1.5	77
18	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72

#	Article	IF	Citations
19	The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 3463-3475.	2.9	69
20	Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: Results of a Canadian multicenter, prospective inception cohort study. Arthritis and Rheumatism, 2009, 61, 1077-1086.	6.7	68
21	Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatric Rheumatology, 2017, 15, 1.	0.9	65
22	Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. Journal of Pediatrics, 1994, 124, 639-642.	0.9	61
23	New-onset juvenile dermatomyositis. Comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1526-1533.	6.7	61
24	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	2.9	59
25	Bone mineral density in juvenile dermatomyositis: Assessment using dual x-ray absorptiometry. Arthritis and Rheumatism, 2003, 48, 2294-2298.	6.7	58
26	Parentâ€“child interactions among children with juvenile fibromyalgia, arthritis, and healthy controls. Pain, 2005, 113, 201-210.	2.0	57
27	Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatric Nephrology, 2005, 20, 368-373.	0.9	51
28	Healthâ€Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care and Research, 2018, 70, 134-144.	1.5	50
29	Seasonal onset of systemic-onset juvenile rheumatoid arthritis. Journal of Pediatrics, 1996, 129, 513-518.	0.9	45
30	Evaluation of a Rheumatology Transition Clinic. Pediatric Rheumatology, 2015, 13, 22.	0.9	41
31	Serum-soluble interleukin-2 receptor levels in Kawasaki disease. Journal of Pediatrics, 1990, 116, 592-596.	0.9	40
32	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
33	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. Pain, 2018, 159, 57-66.	2.0	29
34	Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. Journal of Pediatrics, 1996, 128, 429-432.	0.9	26
35	Prospective Determination of the Incidence and Risk Factors of Newâ€Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort. Arthritis Care and Research, 2019, 71, 1436-1443.	1.5	26
36	Corticosteroid treatment of refractory Kawasaki disease. Journal of Rheumatology, 2006, 33, 803-9.	1.0	25

#	Article	IF	Citations
37	Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort. Journal of Rheumatology, 2019, 46, 628-635.	1.0	24
38	Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections. Arthritis and Rheumatism, 2005, 53, 897-904.	6.7	22
39	Kawasaki Disease in the neonate: case report and literature review. Pediatric Rheumatology, 2018, 16, 43.	0.9	20
40	Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatric Rheumatology, 2012, 10, 31.	0.9	19
41	Glucocorticoidâ€related changes in body mass index among children and adolescents with rheumatic diseases. Arthritis Care and Research, 2013, 65, 113-121.	1.5	18
42	Long-Term Bone Health in Glucocorticoid-Treated Children with Rheumatic Diseases. Current Rheumatology Reports, 2013, 15, 315.	2.1	16
43	Coexpression of chemokine receptors CCR5, CXCR3, and CCR4 and ligands for Pâ€•and Eâ€selectin on T lymphocytes of patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2011, 63, 3467-3476.	6.7	15
44	Worse Quality of Life, Function, and Pain in Children With Enthesitis, Irrespective of Their Juvenile Arthritis Category. Arthritis Care and Research, 2020, 72, 441-446.	1.5	15
45	Realâ€World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. Arthritis Care and Research, 2020, 72, 897-906.	1.5	14
46	The financial burden of juvenile idiopathic arthritis: a Nova Scotia experience. Pediatric Rheumatology, 2013, 11, 24.	0.9	13
47	Clinical characteristics, treatment and outcome of children with Lyme arthritis in Nova Scotia. Paediatrics and Child Health, 2015, 20, 377-380.	0.3	12
48	Recognizing Kawasaki disease. Paediatrics and Child Health, 2001, 6, 638-643.	0.3	11
49	Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2012, 39, 1875-1879.	1.0	11
50	Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 2402-2411.	0.9	11
51	Proposed Core Set of Items for Measuring Disease Activity in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 115-121.	1.0	10
52	Associations of clinical and inflammatory biomarker clusters with juvenile idiopathic arthritis categories. Rheumatology, 2020, 59, 1066-1075.	0.9	9
53	The Accuracy of Prevalent Vertebral Fracture Detection in Children Using Targeted Caseâ€Finding Approaches. Journal of Bone and Mineral Research, 2020, 35, 460-468.	3.1	8
54	A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Arthritis Research and Therapy, 2020, 22, 53.	1.6	8

#	Article	IF	Citations
55	Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 97.	0.9	8
56	A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis and Rheumatology, 2022, 74, 1409-1419.	2.9	7
57	Controversies in the management of Kawasaki disease. Best Practice and Research in Clinical Rheumatology, 2002, 16, 427-42.	1.4	6
58	A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia. Journal of Bone and Mineral Research, 2020, 36, 2290-2299.	3.1	5
59	Parental Perspectives about Research and Knowledge Translation in Juvenile Idiopathic Arthritis. ACR Open Rheumatology, 2020, 2, 138-146.	0.9	4
60	Osteoporotic Fractures and Vertebral Body Reshaping in Children With Glucocorticoid-Treated Rheumatic Disorders. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5195-e5207.	1.8	4
61	Shrinking lung syndrome treated with rituximab in pediatric systemic lupus erythematosus: a case report and review of the literature. Pediatric Rheumatology, 2021, 19, 7.	0.9	3
62	Factors Influencing the Uptake of Canadian Research Findings into the Care of Children with Arthritis: A Healthcare Provider Perspective. Journal of Rheumatology, 2019, 46, 294-300.	1.0	1
63	Pamidronate distribution in pediatric renal and rheumatologic patients. European Journal of Clinical Pharmacology, 2006, 62, 1013-1019.	0.8	0
64	Polyarthritis, Fever and a Rash in a Young Girl. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 73-74.	0.7	0
65	Dr. LeBlanc, et al reply. Journal of Rheumatology, 2013, 40, 339.1-339.	1.0	0
66	Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 760-766.	1.0	0